Sharyn Baker, PharmD, PhD

Sharyn D. Baker, PharmD, PhD

Associate Member, St. Jude Faculty
Director, Pharmacokinetics Shared Resource

Departments

Pharmaceutical Sciences

Contact Information

Sharyn Baker, PharmD, PhD
Pharmaceutical Sciences
MS 314, Room D1034
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: sharyn.baker@stjude.org
Phone: (901) 595-3089
FAX: (901) 595-3125

Education

BA - Pacific Lutheran University, Tacoma, Washington (1986)
PharmD - University of California at San Francisco (1991)
PhD - Erasmus University, Rotterdam, the Netherlands (2004)


Research Interests

  • Clinical Pharmacology of tyrosine kinase inhibitors
  • Tyrosine kinase inhibitors for the treatment of childhood acute myelogenous leukemia
  • Pharmacokinetic variability of anticancer agents

Selected Publications

Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009 NIHMSID: 124864.

Baker SD, Hu S. Pharmacokinetic considerations for new targeted therapies. Clin Pharmacol Ther 85:208-11, 2009 PMID: 19092780. PMCID: PMC2628961

Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. Pharmacogenetic Pathway Analysis of Docetaxel Elimination. Clin Pharmacol Ther 85:155-63, 2009 PMID: 18509327

Minkin P, Zhao M, Chen Z, Ouwerkerk J, Gelderblom H, Baker SD. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry (LC/MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 874:84-8, 2008. PMCID: PMC2612784

Navid F, Christensen R, Minkin P, Stewart C, Furman WL, Baker SD. Stability of Sunitinib in Oral Suspension. Ann Pharmacother 42:962-6, 2008.

Hooker AC, ten Tije AJ, Carducci MA, Weber J, Garrett-Mayer, Gelderblom H, McGuire WP, Verweij J, Karlsson MO, Baker SD. Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements. Clin Pharmacol Ther 84:111-8, 2008.

Hu S, Niu H, Minkin P, Orwick S, Shimada A, Inaba H, Dahl GVH, Rubnitz J, Baker SD. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther 7:1110-20, 2008.

Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD. Sparreboom A. Interaction of Imatinib with Human Organic Ion Carriers. Clin Cancer Res 14:3141-8, 2008.

Smith NF, Baker SD, Harris JW, Figg WD, Sparreboom A. Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. Br J Cancer 98:1630-2, 2008.

Li J, Jameson MB, Baguley BC, Pili R, Baker SD. Population pharmacokinetic-pharmacodynamic (PK-PD) model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in cancer patients. Clin Cancer Res 14:2102-10, 2008.

Gregorc V, Hidalgo M, Spreafico A, Cusatis G, Ludovini V, Ingersoll RG, Marsh S, Steinberg SM, Viganò MG, Ghio D, Villa E, Sparreboom A, Baker SD. Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib. Clin Pharmacol Ther 83:477-84, 2008.

van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, Nortier JW, Guchelaar HJ, Baker SD, Sparreboom A. Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. Clin Cancer Res 13:7394-400, 2007.

Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD. Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese. J Clin Oncol 25:4707-13, 2007.

Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P-450 enzymes. Clin Cancer Res 13:3731-7, 2007.

Li J, Cusatis G, Robey R, Bates S, Sparreboom A, Hidalgo M, Baker SD. Identification of ABCG2 as a high-affinity efflux transporter of the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol Ther 6:432-8, 2007.

Zhao M, Rudek MA, He P, Hafner FT, Radtke M, Wright JJ, Smith BD, Messersmith WA, Hidalgo M, Baker SD. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 846:1-7, 2007.

Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Hidalgo M, Verweij J, Ludovini V, Vila E, Sparreboom A, Baker SD. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98:1739-1742, 2006.

Li J, Karlsson MO, Brahmer J, Spitz A, Zhao M, Hidalgo M, Baker SD. CYP3A4-phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 98:1714-1723, 2006.

Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker SD, Zahurak M, Carducci MA. Phase II Evaluation of Docetaxel plus Exisulind in Patients with Androgen Independent Prostate Carcinoma. Am J Clin Oncol 2006 (in press).

Lepper ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib in patients with gastrointestinal stromal tumors. Clin Pharmacol Ther  2006 (in press).

Hurria A, Fleming MT, Baker SD, Kelly WK, Cutchall K, Panageas, Caravelli J, Yeung JH, Kris M, Gomez J, Miller V, D’Andrea G, Scher HI, Norton L, Hudis C. Pharmacokinetics and Toxicity of Weekly Docetaxel in the Elderly. Clin Cancer Res 2006 (in press).

Gilbert J, Dees EC, Carducci MA, Baker SD, Summerson L, Izumi T, Kobayashi T, Donehower RC. A Phase I Study of the Oral Antimetabolite, CS-682, Administered Once Daily for 5 Days per Week in Patients with Refractory Solid Tumor Malignancies. Invest New Drugs 2006 Jun 21; [Epub ahead of print].

Rudek MA, Zhao M, He P, Messersmith WA, Baker SD. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies. J Pharm Biomed Anal 2006 Jun 7; [Epub ahead of print].

Lee CKK, Rowinsky EK, Li J, Gile F, Moore JJ, Chu E, Hidalgo M, Capparelli E, Jolivet J, Baker SD. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clin Cancer Res Clin Cancer Res 12:2158-65, 2006.

Li J, Brahmer J, Messersmith W, Hidalgo M, Baker SD. Binding of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, to plasma proteins and blood cells: in vitro and clinical pharmacokinetic studies. Invest New Drugs 24:291-7, 2006.

Messersmith WA, Baker SD, Dinh K, Lassiter LK, Akdamar RA, Wright JJ, Donehower RC, Carducci MA, Armstrong DK. Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12:1270-5, 2006.

Mita AC, Sweeney CJ, Baker SD, Goetz A, Felton S, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Johnson RD, Rowinsky EK, Takimoto CH. A Phase I and Pharmacokinetic Study of Pemetrexed Administered Intravenously Every 3 Weeks to Advanced Cancer Patients with Impaired Renal Function. J Clin Oncol 24:552-562, 2006.

Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Huso D, Baker SD, Barber J, Jaffee E, Reilly RT, Sukumar S. Ductal access for prevention and therapy of mammary tumors. Cancer Res 66:638-45, 2006.

Sweeney CJ, Takimoto CH, Latz JE, Baker SD, Murry D, Krull JH, Fife K, Battiato L, Cleverly A, Chaudhary AK, Chaudhuri T, Sandler A, Mita AC, Rowinsky EK. Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed when Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer. Clin Cancer Res 12:536-42, 2006.

2000-2005 publications

Last update: July 2009

Email This Article Email This Article   |   Print Print